Document Type : Original Article
Authors
1
Lecturer of Pathology, Faculty of Medicine, Benha University, Benha, Egypt
2
Assistant Professor of Pathology, Faculty of Medicine, Benha University, Benha, Egypt
3
Lecturer of Clinical Pathology, National Cancer Institute, Cairo University, Cairo, Egypt
4
(M., B., B.CH), Demonstrator of Pathology, Faculty of Medicine, Benha University
5
Professor of Pathology, Faculty of Medicine, Benha University, Benha, Egypt
Abstract
Background: 1% of all cancers and about 10% of all haematologic malignancies are multiple myeloma (MM). In various human cancers, including multiple myeloma, abnormal expression or deregulation of JAM-A, which controls cell growth and differentiation, results in a more aggressive phenotype and poor prognosis. Aim: to evaluate the immunohistochemical expression of JAM-A in cases of multiple myeloma and correlate its expression with variable clinicopathological parameters to assess its possible diagnostic and prognostic role and hence therapeutic modalities. Material and method: This is a selected retrospective immunohistochemical study of JAM-A performed on 40 cases of MM. Results: There is a statistically significant direct correlation between JAM-A overexpression and older Age (P= .022), histological type (immature & plasmablastic)(P=.020), diffuse pattern of infiltration(P=.016), increased BMB cellularity(P=.017), higher ISS Stage (P=.033), advanced R- ISS Stage (P=.042), No Complete response(P=.008), more Resistance to therapy (P= .032), Karyotyping result (P=.019), short survival (P= .014). Conclusion: JAM-A overexpression might have an important role in proliferation, invasion, progression, poor outcome of multiple myeloma cases. So, JAM-A might have a promising value in treatment of MM.
Keywords
)
View on SCiNiTO